The incidence of non-ovarian cancers in women with a CA125 <35 U/ml was 2.0%, whereas the incidence in women with a CA125 ≥35 U/ml, which equates to the PPV for non-ovarian cancers, was 12.3% (95% CI 11.2–13.5) (Table 3). This evidence concerns the gene MUC16 and ovarian cancer.